il 33

Tozorakimab (MEDI-3506) 是一种针对 IL-33 的人免疫球蛋白 G1 单克隆抗体，通过 ST2 和 RAGE EGFR 抑制 IL-33 信号传导，减轻炎症和上皮功能障碍，可用于研究慢性阻塞性肺病。

Dupilumab (REGN-668) 是一种用于AD 的全身免疫调节剂。Dupilumab 是一种针对白细胞介素-4受体α亚基的完全人类单克隆抗体，可抑制IL-4和IL-13下游信号传导，具有改善特应性皮炎的作用。

CB2 receptor agonist 9 (Compound 33) 是一种有效的口服大麻素受体 2 (CB2 receptor) 激动剂，EC50 为 16.2 nM。CB2 receptor agonist 9 能抑制 TNF-α、IL-1β 和 IL-6 的表达，并在 DDS 诱导的小鼠急性结肠炎模型中显示抗炎活性。

Torudokimab (ZB-880) 是一种中和白细胞介素 33 的单克隆抗体，可用于研究免疫系统疾病和呼吸系统疾病。

AC708 is a small molecule CSF1R inhibitor that effectively inhibits CSF1R phosphorylation mediated by CSF-1 (IC50 = 26 nM) and IL-34 (IC50 = 33 nM). It also inhibited the activity of growth factor-dependent cells cultured in CSF-1 (IC50 = 38 nM) or IL-34

NLRP3-IN-58（Compound DS15）作为NLRP3炎症小体（NLRP3 inflammasome）的激活抑制剂，表现出IC50为3.85 μM的效力，并能在10 μM的浓度下抑制33%的IL-1β释放。

ST2-IN-1 (compound 31)，作为Stimulation-2 (ST2)的抑制剂，其在AlphaLISA测定中展现出7 μM的IC50值，并在HEK-Blue测定中显示7.19 μM的IC50。此化合物能有效抑制人类肥大细胞中的ST2 IL-33信号传递。

S7是一种IL-6受体的肽类拮抗剂，能够浓度依赖性地抑制IL-6与IL-6受体的结合。在C-33 A宫颈癌细胞和RPMI-8226 B细胞淋巴细胞中，S7 (50 µM) 能抑制IL-6诱导的VEGF水平增加。在每两天给药一次，剂量为50 mg/kg的条件下，S7能减少IL-6过表达的C-33 A宫颈癌小鼠异种移植模型中的肿瘤体积。当S7与半胱氨酸结合，并连接到包裹多柔比星的脂质纳米粒子(LNPs)表面时，能增强LNPs对胶质瘤的靶向性，并在U251胶质母细胞瘤小鼠异种移植模型中提高生存率。

HPK1-IN-33（化合物21）是造血祖细胞激酶1（HPK1）的高效抑制剂，其Ki值为1.7 µM。此化合物在Jurkat WT细胞中抑制IL-2产生的EC50为286 nM，而在Jurkat HPK1 KO细胞中的EC50则大于10000 nM。

SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPAR) but does not activate it. SR-1903 inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1). It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1. SR-1903 reduces the severity of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.

Tetranactin is a macrotetrolide and a monovalent cation ionophore that has been found in S. aureus and has antibacterial, insecticidal, and mitogenic activities. It exhibits an equilibrium permeability ratio 1,000-fold greater for lithium than sodium or cesium ions accross bilayer membranes at low voltages. Tetranactin inhibits the growth of Gram-positive bacteria and C. miyabeanus and R. solani fungi when used at concentrations less than 0.9 μg/ml. Tetranactin (0.5-1.5 μg per insect) dose-dependently increases the mortality of adult C. chinensis weevils up to 100% and has mitogenic activity against T. telarius when sprayed onto plants with an LC50 value of 9.2 μg/ml. It reduces IL-1β- and cAMP-induced secretion of phospholipase A2 (PLA2) from rat mesangial cells (IC50s = 43 and 33 nM, respectively). Tetranactin (50 ng/ml) suppresses the proliferation of human T lymphocytes induced by allogeneic cells and IL-2 and supresses the generation of cytotoxic T lymphocytes in mixed lymphocyte cultures. In vivo, tetranactin (10 mg/animal per day) completely inhibits the formation of experimental autoimmune uveoretinitis (EAU) in rats.

SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).

Astegolimab (RG 6149) 是一种人源化靶向 IL-33 受体的 IgG2 单克隆抗体，可抑制 IL-33 信号传导。Astegolimab 可用于研究慢性阻塞性肺疾病 (COPD) 和成人严重哮喘。

Itepekimab (REGN-3500) 是一种有效的抗 IL-33 的单克隆抗体。Itepekimab 在体内实验中可减少气道炎症和相关组织损伤，可用来研究哮喘疾病。

Etokimab（Antibody ANB 020），一种人源化单克隆抗体，靶向IL-33，主要用于特应性皮炎的研究。